Cliquez sur les images pour acquérir mes livres : frais de port gratuits et envoi rapide.

Pour suivre mon actualité ou me contacter : sur Facebook.

Traitement long terme de GH: l’incidence sur la mortalité est digne de la roulette russe

15/06/2016 | Etudes sur les hormones et Etudes Anti-âge

 

Mortality and cancer incidence among patients treated with recombinant growth hormone during childhood in Israel
Clinical Endocrinology 13 June 2016     Carmit Libruder

Context

The inconclusive evidence regarding long term safety of rhGH therapy underlines the need for long-term large-scale cohorts.
Objective

To assess long term mortality and cancer incidence among patients treated with rhGH during childhood in Israel.
Design: A population-based cohort study.
Setting: Data were retrieved from a national register established in 1988. Mortality data from the national population register were available through December 31st, 2014. Data on cancer incidence from the national cancer registry were available through December 31st, 2012.

Participants: All patients ≤19 years approved for rhGH treatment during 1988-2009 were included. Patients were assigned to three risk categories, according to the underlying condition leading to growth disorder.
Main Outcome Measures

All-cause mortality and cancer incidence rates were calculated, based on person-years at risk. Standardized mortality ratios (SMRs) and standardized incidence ratios (SIRs) were calculated, using the Israeli general population as a reference.

Results

Included were 1,687 patients assigned to the low risk category and 440 patients assigned to the intermediate risk category. In the low risk category, all-cause mortality and cancer incidence were lower than expected (SMR 0.81, 95% CI 0.22-2.08 and SIR 0.76, 95% CI 0.09-2.73).
In the intermediate risk category, all-cause mortality and cancer incidence were significantly higher than expected (SMR 4.05, 95% CI 1.62-8.34 and SIR 4.52, 95% CI 1.22-11.57).

Conclusions

No increased risk of mortality or cancer incidence was found in low risk patients treated with rhGH during childhood. Patients with prior risk factors were at higher risk of both mortality and cancer.

Partagez :

Voir aussi :


Commenter

Commenting is not available in this weblog entry.